Age
Item
1. subjects must be between the ages of 18 and 80 inclusive.
boolean
C0001779 (UMLS CUI [1])
Standard criteria for parkinson's disease
Item
2. each subject must meet standard criteria for pd.
boolean
C0243161 (UMLS CUI [1,1])
C0030567 (UMLS CUI [1,2])
Benefit from dopaminergic therapy
Item
3. all patients on dopaminergic therapy must report benefit. -no other abnormal neurological signs. -no direct or indirect trauma to the nervous system within 3 months preceding the onset of pd. -no convincing evidence of sudden onset or evidence of stepwise deterioration.
boolean
C0013036 (UMLS CUI [1,1])
C0814225 (UMLS CUI [1,2])
Health Status
Item
4. subjects must be in generally good health as evidenced by previous medical history and clinical examination.
boolean
C0018759 (UMLS CUI [1])
Pharmacotherapy for Parkinson except amantadine; pharmacotherapy for alzheimer's disease
Item
5. subjects will be allowed to take any pd medication with the exception of amantadine. they will also be allowed to take medications approved for the use of alzheimer's disease.
boolean
C0013216 (UMLS CUI [1,1])
C0030567 (UMLS CUI [1,2])
C0332300 (UMLS CUI [1,3])
C0002403 (UMLS CUI [1,4])
C0013216 (UMLS CUI [2,1])
C0002395 (UMLS CUI [2,2])
Stable dosage
Item
6. subjects will be required to be on a stable dose of all medications for at least two weeks prior to entry into the study and may not alter these medications throughout the study.
boolean
C0205360 (UMLS CUI [1,1])
C0178602 (UMLS CUI [1,2])
Antidepressant medication
Item
7. if subjects are on an anti-depressant medications, a stable dose of these will be required for at least six weeks prior to entry into the study.
boolean
C0003289 (UMLS CUI [1])
Telephone
Item
8. subjects must be accessible by telephone.
boolean
C1515258 (UMLS CUI [1])
Contraceptive methods
Item
9. if the subject is a female of childbearing age, she must have had: a hysterectomy, or tubal ligation, or otherwise be incapable or pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry: hormonal contraceptives, spermicide and barrier, intrauterine device, partner sterility.
boolean
C0700589 (UMLS CUI [1])
Pregnancy and Informed Consent
Item
10. female of childbearing age must have had a negative urine pregnancy test within one week of study entry. 11. prior to participation in this study, each subject must sign an informed consent.
boolean
C0032961 (UMLS CUI [1])
C0021430 (UMLS CUI [2])
Inclusion Criteria
Item
1. subjects who do not meet inclusion criteria.
boolean
C1512693 (UMLS CUI [1])
Substance Use Disorder
Item
2. subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation.
boolean
C0038586 (UMLS CUI [1])
Pharmacotherapy affecting Parkinson's disease
Item
3. subjects who can not maintain an identical dose of any medicine that may affect pd symptoms or signs during their entire study involvement.
boolean
C0013216 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0030567 (UMLS CUI [1,3])
Mental disorder and Memantine
Item
4. subjects who have exhibited meaningful psychiatric disease not thought to be related to pd. (depression and psychosis typical for pd will not be excluded). 5. subjects who have previously taken memantine.
boolean
C0004936 (UMLS CUI [1])
C0025242 (UMLS CUI [2])
Amantadine, MMSE, Comorbidity
Item
6. subjects currently taking amantadine. 7. subjects with greater than moderate dementia (mmse<24). 8. subjects with co-morbid disease that in the investigators decision could interfere with treatment with memantine.
boolean
C0002403 (UMLS CUI [1])
C0451306 (UMLS CUI [2])
C0009488 (UMLS CUI [3])